872 results on '"Fuchs, Ephraim"'
Search Results
102. Cryoimmunotherapy in Urologic Oncology
103. B Cells Turn Off Virgin But Not Memory T Cells
104. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis
105. Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL
106. Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching
107. Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
108. The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells
109. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
110. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
111. Transplantation tolerance: from theory to clinic
112. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
113. Haplo graft engineering: sculpting to a T
114. Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma
115. Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens
116. Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use
117. Does Post-Transplantation Cyclophosphamide Inhibit Graft-versus-Leukemia?
118. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
119. 265 - Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
120. 121 - Reduced Intensity Conditioning Substituting Pentostatin for Fludarabine in Allogeneic Blood and Marrow Transplantation (AlloBMT) Is Safe and Effective
121. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells
122. Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions
123. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes
124. Hematopoietic Cell Transplantation from Partially HLA-Mismatched (HLA-Haploidentical) Related Donors
125. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
126. Incidence and Impact of Non-CMV Herpes Viral Infection in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
127. Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
128. A Machine Learning Approach Deciphers the Effects of Immune Parameters on Clinical Outcomes after HLA-Haploidentical and HLA-Matched Allogeneic Bone Marrow Transplantation with Posttransplant Cyclophosphamide
129. Incidence and Impact of Community Respiratory Viral Infection (CRV) in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
130. HLA-mismatched microtransplantation for relapsed or refractory acute myeloid leukemia as a bridge to allogeneic hematopoietic stem cell transplantation
131. Association of Foxp3 regulatory gene expression with graft-versus-host disease
132. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors
133. Chapter 106 - Haploidentical Hematopoietic Cell Transplantation
134. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
135. Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma
136. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
137. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia
138. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
139. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016
140. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
141. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results
142. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
143. T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes
144. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation
145. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
146. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
147. Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
148. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia
149. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
150. Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.